Stellarex drug-coated balloon: a technology evaluation

Area of Science:

• Vascular Medicine
• Interventional Cardiology
• Drug Delivery Systems

Background:

• The Stellarex drug-coated balloon (DCB) is designed for endovascular procedures.
• It features a low-dose paclitaxel coating (2 μg/mm²) on a semi-compliant balloon.
• The hybrid formulation aims to optimize drug release and coating integrity.

Purpose of the Study:

• To evaluate the clinical effectiveness and safety of the Stellarex DCB.
• To assess the drug-coating characteristics and release profile of the device.
• To analyze long-term follow-up data for patients treated with Stellarex.

Main Methods:

• Utilizes an over-the-wire, dual-lumen catheter system.
• Features a hybrid paclitaxel formulation (amorphous and crystalline) with a polyethylene glycol excipient.
• Clinical data from treated patients were analyzed for effectiveness and safety outcomes.

Main Results:

• The hybrid formulation ensures coating integrity during handling and tracking.
• Effective paclitaxel transfer to the vessel wall at the lesion site is achieved.
• Growing clinical data confirm long-term effectiveness of the Stellarex DCB.

Conclusions:

• The Stellarex DCB demonstrates sustained clinical effectiveness.
• Long-term follow-up data indicate a positive safety profile for treated patients.
• The device's formulation supports reliable drug delivery and therapeutic outcomes.